1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;388:2039-52. https://doi.org/10.1016/S0140-6736(16)00346-9;
2. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46. https://doi.org/10.1002/acr.21772;
3. Merriman TR. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther 2015;17:98. https://doi.org/10.1186/s13075-015-0609-2;
4. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414. https://doi.org/10.1023/B:CARD.0000015855.02485.e3;
5. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017;15:123. https://doi.org/10.1186/s12916-017-0890-9;